X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VX-548 (suzetrigine) is an investigational oral, selective NaV1.8 inhibitor, which is currently being evaluated for the treatment of patients with moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
VX-548 (suzetrigine) is a selective NaV1.8 inhibitor, which is being evaluated in phase 3 clinical trials for the treatment of moderate-to-severe acute pain.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
VX-548 is an investigational oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8. It is under clinical development for the treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2022
Details:
VX-548 was generally well tolerated in both studies. Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548. Fewer patients discontinued treatment in the mid- and high-dose VX-548 arms than in the placebo group.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The Phase 2 studies are randomized, double-blind, placebo-controlled trials that will evaluate multiple doses of VX-548 in patients with acute pain following bunionectomy surgery or abdominoplasty surgery.
Lead Product(s): Suzetrigine
Therapeutic Area: Neurology Product Name: VX-548
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
